



Levonorgestrel-containing intrauterine systems Comparison table

	Kyleena®	Levosert®	Mirena®
Formulary position	First choice	Alternative	Alternative
Levonorgestrel dose (total)	19.5 mg	52 mg	52 mg
Levonorgestrel dose (daily) NB: dose varies over lifetime of device	7.4-17.5 micrograms (9.0 micrograms on average)	9.8-19.5 micrograms (14.7 micrograms on average)	10-20 micrograms (14 micrograms on average)
Indications	<ul style="list-style-type: none"> Contraception 	<ul style="list-style-type: none"> Contraception Heavy menstrual bleeding 	<ul style="list-style-type: none"> Contraception Heavy menstrual bleeding Endometrial protection during oestrogen HRT
Duration	Up to five years	Up to five years	Up to four years (HRT) Up to five years (other indications)
Cost	£76 + VAT	£66 + VAT	£88 + VAT
Cost per year	£15.20	£13.20	£22.00 (over four years) £17.60 (over five years)
Size Insertion tube diameter	28 x 30 mm 3.8 mm	32 x 32 mm 4.8 mm	32 x 32 mm 4.4 mm
Contraceptive efficacy (Pearl Index†)	1 year: 0.16 5 years: 0.29	1 year: 0.15 5 years: 0.20	1 year: 0.2 5 years: 0.7
Safety information	Levonorgestrel-releasing IUS should always be prescribed by brand name because products have different indications, durations of use, and introducers (See Drug Safety Update , January 2016) Before inserting an IUS or IUD, inform women of the risk of and risk factors for perforation (See Drug Safety Update , June 2015)		
Other information	One handed EvoInserter™	Two-handed inserter	One handed EvoInserter™

To be read in conjunction with the [product information](#)



Levonorgestrel-containing intrauterine systems Comparison table

	Kyleena®	Levosert®	Mirena®
Silver ring for improved visibility on ultrasound?	Yes	No	No
Visible on X-ray?	Yes	Yes	Yes
Other information	Placement considered by clinicians to be easier than for Mirena (94% vs. 86% rated as “easy”, p<0.001). Women more likely to report no pain or mild pain during placement than for Mirena (72% vs. 58%, p<0.001)	Minimum uterine depth: 5.5 cm.	

† The Pearl Index is a measure of contraceptive efficacy essentially equivalent to the annual pregnancy risk if 100 women were to use a specific method of contraception.

Additional information is available from the Faculty of Sexual and Reproductive Healthcare:

- FSRH New Product Review: Kyleena® 19.5mg levonorgestrel-releasing intrauterine system. January 2018, amended March 2019. <https://www.fsrh.org/news/fsrh-ceu-new-product-review-kyleena-195mg-levonorgestrel/>
- FSRH New Product Review: Levosert® Levonorgestrel Intrauterine Delivery System LNG IUS. April 2015, amended March 2019. <https://www.fsrh.org/standards-and-guidance/documents/new-product-review-levosert-intrauterine-delivery-system-april/>
- FSRH Clinical Guideline: Intrauterine Contraception. April 2015, amended October 2015. <https://www.fsrh.org/standards-and-guidance/documents/ceuguidanceintrauterinecontraception/>

To be read in conjunction with the [product information](#)